Status:
TERMINATED
Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study
Lead Sponsor:
Amsterdam UMC, location VUmc
Collaborating Sponsors:
Medical Research Foundation, The Netherlands
Bristol-Myers Squibb
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The ATIC study is a randomised, double- blind, placebo-controlled trial in which the effects of oxidative stress-lowering treatment on vascular function and structure are studied in patients with chro...
Detailed Description
Background: Patients with mild-to-moderate renal failure have an increased risk of cardiovascular disease (CVD), which is not fully explained by the presence of classical cardiovascular risk factors. ...
Eligibility Criteria
Inclusion
- chronic
- kidney disease (clearence between 15-70ml/min)
Exclusion
- diabetes mellitus (ADA criteria), active vasculitis, nephrotic syndrome (\>3g protein/24h urine), renal transplantation, fasting total cholesterol \> 7 mmol/L, cholesterol-lowering therapy within three months prior to inclusion or known ischaemic coronary, cerebrovascular or peripheral arterial disease
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00384618
Start Date
May 1 2001
End Date
August 1 2005
Last Update
October 6 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, North Holland, Netherlands, 1007 MB